Skip to main content

Table 1 Patient characteristics

From: Does antithrombotic therapy improve survival with colorectal cancer?

Characteristic Overall, n = 710 Antithrombotic therapy, n = 246 Control, n = 464 p value
Age (years, mean ± SD)   73.8 ± 7.8 68.6 ± 11.6 0.01
Gender (n, %) Male 183(74.3) 276 (59.4)  
  Female 63 (25.7) 188 (40.6) 0.01
BMI (kg/m2, mean ± SD)   22.3 ± 3.4 23.6 ± 6.7 0.57
ASA score (n, %) 1 0 (0) 63 (13.5)  
  2 0 (0) 366 (78.9)  
  3 225 (91.5) 22 (5.0)  
  4 21 (8.5) 13 (2.6) 0.01
Comorbidities (n, %) ≤1 18 (7.3) 98 (21.1)  
  >1 228 (92.7) 366 (78.9) 0.02
Tumor location (n, %) Right side 103 (41.5) 209 (45.0)  
  Left side 67 (27.6) 102 (22.0)  
  Rectum 76 (30.9) 153 (33.0) 0.37
Extended resection (n, %) Yes 22 (8.9) 63 (13.5)  
  No 224 (91.1) 401 (86.5) 0.07
Laproscopic surgery (n, %) Yes 52 (21.1) 121 (26.0)  
  No 194 (78.9) 343 (74.0) 0.14
Chemotherapy (n, %) Yes 120 (48.7) 268 (57.7)  
  No 126 (51.3) 196 (42.3) 0.02
Recurrence (n, %) Yes 36 (14.6) 98 (21.1)  
  No 210 (85.4) 366 (78.9) 0.03
T stage (n, %) 0 9 (3.6) 11 (2.3)  
  1 50 (20.3) 82 (17.6)  
  2 34 (13.8) 44 (9.5)  
  3 100 (40.6) 198 (42.7)  
  4 53 (21.7) 128 (27.9) 0.15
N stage (n, %) 0 146 (59.3) 281 (60.5)  
  1 60 (24.3) 103 (22.2)  
  2 33 (13.4) 63 (13.5)  
  3 7 (3.0) 16 (3.8) 0.9
M factor (n, %) 0 220 (89.4) 396 (85.3)  
  1 26 (10.6) 67 (14.7) 0.14
The number of lymph node metastasis (n, %)   1.59 ± 3.15 1.47 ± 2.81 0.6
Lymph node metastasis (n, %) Yes 103 (41.8) 179 (38.5)  
  No 143 (58.2) 285 (61.5) 0.39
Stage (n, %) 0 9 (3.6) 11 (2.4)  
  I 65 (26.4) 114 (24.6)  
  II 65 (26.4) 142 (30.6)  
  IIIa 54 (21.9) 87 (18.7)  
  IIIb 21 (8.5) 37 (8.0)  
  IV 32 (13.2) 72 (15.7) 0.59
ly (n, %) 0 67 (27.2) 106 (22.8)  
  1 140 (56.9) 252 (54.3)  
  2 33 (13.4) 89 (19.2)  
  3 6 (2.5) 16 (3.7) 0.15
v (n, %) 0 116 (47.2) 202 (43.5)  
  1 62 (25.2) 118 (25.4)  
  2 61 (24.8) 121 (26.1)  
  3 7 (2.8) 22 (5.0) 0.55
R (n, %) 0 222 (90.2) 399 (86.0)  
  1 24 (9.8) 64 (14.0) 0.22
Histrogical type (n, %) Well 212 (86.2) 398 (84.3)  
  Other 34 (13.8) 66 (15.7) 0.88
Poorly differentiated adenocarcinoma (n, %) Yes 18 (7.3) 43 (9.2)  
  No 228 (92.7) 421 (90.8) 0.37
Mucinous adenocarcinoma (n, %) Yes 19 (7.7) 31 (6.7)  
  No 227 (92.3) 433 (93.3) 0.61